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Abstract
Objective: Our objective was to establish genotypic resistance profiles among the 4% of Batswana patients who experienced
virologic failure while being followed within Botswana's National Antiretroviral Treatment Program between 2002 and 2007.
Methods: At the beginning of the national program in 2002, almost all patients received stavudine (d4T), together with
didanosine (ddI), as part of their first nucleoside reverse transcriptase inhibitor (NRTI)-based regimen (Group 1). In contrast,
the standard of care for all patients subsequently enrolled (2002-2007) included zidovudine/lamivudine (ZDV/3TC) (Group 2).
Genotypes were analyzed in 26 patients from Group 1 and 37 patients from Group 2. Associations between mutations were
determined using Pearson's correlation coefficient and Jaccard's coefficient of similarity.
Results: Seventy-eight percent of genotyped patients possessed mutations associated with protease inhibitor (PI) resistance
while 87% and 90%, respectively, exhibited mutations associated with NRTIs and non-nucleoside reverse transcriptase inhibitors
(NNRTIs). The most frequent PI mutations involving resistance to NFV were L90M (25.2%) and D30N (16.2%), but mutations
at positions K45Q and D30N were often observed in tandem (P = 60.5, J = 50; p = 0.002; Group 2) alongside Q61E in 42.8%
of patients who received ZDV/3TC. Both major patterns of thymidine analogue mutations, TAM 1 (48%) and TAM 2 (59%),
were represented in patients from Group 1 and 2, although M184V was higher among individuals who had initially received ddI
(61% versus 40.5%). In contrast, L74V was more frequent among individuals from Group 2 (16.2% versus 7.7%). Differences in
regard to NNRTI mutations were also observed between Group 1 and Group 2 patients.
Conclusion: Despite a low rate of therapeutic failure (4%) among these patients, those who failed possessed high numbers of
resistance mutations as well as novel resistance mutations and/or polymorphisms at sites within reverse transcriptase and
protease.
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Background
Botswana has an approximate 30% seroprevalence for
HIV-1 [1] and was also one of the first African countries to
provide universal free access to antiretroviral therapy
(ART) in 2002. Prior to 2002, most patients in Botswana
initiated therapy with d4T/ddI-based regimens. From Jan-
uary 2002, the main first-line regimen in Botswana was
ZDV/3TC plus either efavirenz (EFV) or nevirapine (NVP)
in women in whom pregnancy was likely to occur. For
patients failing initial regimens, the main second-line reg-
imen was d4T/ddI plus nelfinavir (NFV). More recently,
lopinavir/ritonavir (LPV/r) has been approved for use in
second-line to replace NFV, while tenofovir (TDF)/3TC is
now used as a nucleoside reverse transcriptase inhibitor
(NRTI) backbone in first-line [2].
By March 2007, 84,927 patients had entered the national
ART programme, while an additional 9,514 had been fol-
lowed in the private sector. The percentage of patients
receiving therapy is estimated to be greater than 80% of
the total need [3]. As of April 2007, a total of 17,400
patients had been registered at the Adult Infectious Dis-
ease Care Clinic (IDCC) located at the Princess Marina
Hospital in Gaborone. Among these, approximately
11,000 were receiving comprehensive HIV treatment and
care. This site has also launched a treatment failure proto-
col that has ascertained the treatment failure rate among
ARV patients to be 4% [4].
Both acquired [5] and transmitted [6] drug resistance rep-
resent obstacles for the long-term use of ARVs. Previous
publications from the IDCC described the frequencies
and patterns of mutations in the reverse transcriptase (RT)
and protease (PR) genes [7-9]. In general, no major
impact of HIV subtypes has been observed regarding drug
susceptibility [10,11].
We previously demonstrated that d4T/ddI-based regi-
mens were associated with high rates of selection of the
K65R mutation in HIV-1 subtype C [8,12]. For purposes
of this analysis, patients failing therapy have been divided
into those who received d4T/ddI as part of their first regi-
men (Group 1) versus those who initiated therapy with
ZDV/3TC and who received ddI as part of second or sub-
sequent regimens (Group 2). We also attempted to delin-
eate associations between different mutations that are
involved in drug resistance, as has already been calculated
in subtype B viruses [13-15].
Methods
Patients and HIV-1 subtype C sequencing
Among the 4% of Batswana patients who experienced
treatment failure at the IDCC, 363 received a ddI-based
regimen as part of their first (Group 1) or second or sub-
sequent regimen (Group 2). As recommended by the Bot-
swana national programme since March 2005, all patients
experiencing virological failure after their second-line reg-
imen, mostly containing NFV as a first PI were evaluated
by genotyping, viz., a total of 63 patients (27 in Group 1
and 36 in Group 2).
These genotypes were linked to patients' demographic,
immunologic, virologic and therapeutic clinical data. HIV
genotyping for drug resistance was performed on plasma
samples using a commercially available kit (ViroSeq HIV-
1 genotyping system; Abbott Laboratories). All the
patients were confirmed as possessing subtype C viruses
on the basis of nucleotide sequence alignment using the
ClustalX-version 1.8 sequencing tool [16]. The neighbour-
joining method was employed for phylogenetic tree
building using the NJplot programme.
Statistical and mutational covariate analysis
We first calculated the frequencies of RT and PR mutations
in the pol  sequences of 26 Group 1 and 37 Group 2
patients who were followed. We also established relation-
ships between the presence of specific mutations using
both the Pearson correlation coefficient (P) and the Jac-
card similarity coefficient (J). A Fisher's exact test was also
performed to assess the significance of any associations
that were found. As a reference, we employed the 2008
IAS-USA list of mutations [17].
Results
Patient characteristics
The characteristics of the 63 patients followed in this
study are shown in Table 1, with virologic failure being
defined as the inability to suppress plasma viremia or the
rebound of viral load (VL) on at least two consecutive
occasions to levels >400 copies RNA/ml. Median CD4 cell
counts at failure were 334 cells/mm3 for Group 1 and 233
cells/mm3 for Group 2 and medians of viral loads (log10
HIV-1 RNA copies/ml) were 4.2 and 4.7 for Group 1 and
2, respectively, at which time most patients had received
three different treatment regimens.
Mutations to protease inhibitors
Phylogenetic analysis indicated that all of the 63 patients
who were genotyped possessed subtype C viruses. Approx-
imately 78% of PI-treated individuals exhibited resistance
mutations; similar patterns of resistance were observed
among both groups (Figure 1). Among patients who
received NFV, the most common mutations observed
were D30N and L90M, consistent with previous results
(Table 2).
Interestingly, 43% of patients possessed a Q61E mutation
(CAA → GAA) that emerges from a silent substitution, i.e.,
CAA in subtype C relative to CAG in subtype B. The I62V
resistance mutation was present in 11% of those patientsJournal of the International AIDS Society 2009, 12:25 http://www.jiasociety.org/content/12/1/25
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who only received NFV as a PI. We confirmed the correla-
tion seen by others between D30N and N88D (P = 74 and
52.4, J = 60 and 33.3; p = 0.004 and 0.01 for Groups 1 and
2, respectively) and also observed a novel association
between D30N and K45Q (P = 60, J = 50; p  = 0.002;
Group 2), while L89I was only found in association with
D30N (P = 50.5, J = 50; p = 0.002; Group 2) (Table 3).
Mutations to reverse transcriptase inhibitors
Approximately 87% of the patients who were genotyped
possessed mutations associated with resistance to
NNRTIs, while 90% presented with mutations associated
with NRTIs (Table 4, Figure 2). Some individuals in
Group 2 possessed I202V, L228R/H and D324E substitu-
tions. M184V was observed in 16 of 26 Group 1 patients,
14 of whom had received 3TC prior to genotyping. In
patients from Groups 1 and 2, both TAM 1 (48%) and
TAM 2 (59%) mutations were present.
Similarly, 10 of 15 Group 2 patients who possessed
M184V had been on a 3TC-containing regimen at the time
of testing. Only two patients carried the K65R mutation;
one of these had received TDF and the other had received
ddI at the time of genotyping. The length of time on inef-
fective regimens (based on non-suppressed VL) was 809
days and 279 days for Groups 1 and 2, respectively.
Patients with the L74V mutation (16.2% in Group 2) were
on ABC/ddI at the time of genotyping. In the group of
patients who received EFV, the most frequent mutations
Table 1: Characteristics of the 63 patients who received ddI/d4T (Group 1) versus ZDV/3TC (Group 2) as first-line therapy
Group 1
(n = 26)
Group 2
(n = 37)
Age (years)
Median
Interquartile range
35
[24-57]
34
[21-48]
Female sex (%) 61.5 60.7
Baseline nadir CD4 cell count
Median
Interquartile range
96 [2-276] 61
[1-317]
CD4 cell count at failure visit
Median
Interquartile range
334
[41-937]
233
[9-1313]
Log10 HIV-1 RNA at failure visit
Median
Interquartile range
4.2
[2.9-5.33]
4.7
[3.5-5.9]
Total days on antiretroviral therapy at the time of genotype
Median Interquartile range
998
[228-2507]
486
[59-1346]
Total time (days) to non-detectability of viral load (<400 copies/ml) at the time of genotype
Median
Interquartile range
158
[28-1693]
96
[10-1188]
Average number of ARV regimens received by the time of genotype 3* 2.5†
*Group 1 - ARV regimens received by the time of genotyping. ddI/d4T/NVP, ZDV/3TC/EFV, ddI/d4T/NFV; ddI/d4T/NVP, ZDV/3TC/NVP, d4T/
3TC/NVP, ABC/ddI/NFV; ddI, ddI/d4T/NVP; ddI/ZDV, ddI/d4T/EFV, ZDV/3TC/NFV; ddI/ZDV/3TC, ZDV/3TC/NVP, ABC/ddI/NFV; ddI/d4T/EFV, 
ZDV/3TC/EFV, ddI/d4T/NFV; ddI/d4T/NVP, ZDV/3TC/NFV (n = 2); ddI/d4T, ZDV/3TC/NVP, ddI/TDF/LPVr; ddI/d4T/EFV, ZDV/3TC/EFV (n = 3); 
ddI/ZDV, ZDV/3TC/NVP, ddI/d4T/NFV; ddI/d4T/NVP, ZDV/3TC/NFV, LPVr/SQV; ddI/ZDV/NVP, 3TC/d4T/NFV; ddI/d4T, ZDV/3TC/EFV, ddI/
d4T/SQV/RTV; ddI/d4T/NVP, ZDV/3TC/NFV, ZDV/TDF/LPVr; ddI/ZDV/NVP, 3TC/d4T/IDV/RTV; ddI/d4T/EFV, ddI/d4T/NFV; ddI/d4T, ddI/d4T/
NVP, ZDV/3TC/EFV; ddI/d4T/NVP, ZDV/3TC/NVP; ddI/d4T, 3TC/ddI, ZDV/3TC/NVP, ZDV/3TC/EFV; ddI/d4T, ZDV/3TC/SQV/RTV, ZDV/3TC/
NVP; ddI/d4T/EFV, ZDV/3TC/EFV, ABC/ddI/NFV, ddI/d4T/EFV/LPV; ddI/d4T/EFV, ABC/ddI/NFV, d4T/3TC/EFV; ddI/ZDV/NVP, d4T/3TC/IDV, ddI/
d4T/NFV.
†Group 2 - ARV regimens received by the time of genotyping. ZDV/3TC/NVP; ZDV/3TC/NVP, ddI/d4T/NVP, ZDV/3TC/NVP, 3TC/ddI/NFV, 3TC/
ABC/ddI/LPV; ZDV/3TC/NVP, ddI/d4T/NFV (n = 13); ZDV/SQV/RTV, ddI/d4T, ddI/d4T/NFV, 3TC/ABC/LPV; ZDV/3TC/EFV, ddI/TDF/LPV; ZDV/
3TC/IDV, ZDV/3TC/NVP, ddI/d4T/NVP; ABC/ddI/NVP; 3TC/d4T/NVP, ZDV/ddI/NFV; ZDV/3TC/NVP, ddI/d4T/NFV, ZDV/3TC/LPV; ZDV/3TC/
EFV, ddI/d4T/NFV (n = 5); ZDV/3TC/NVP, ddI/d4T/NFV, ABC/SQV/RTV; ZDV/3TC/NVP, ddI/d4T/NFV, ABC/ddI/NFV; ZDV/3TC, SQV/RTV, ddI/
d4T/SQV/RTV, ABC/d4T/ddI/LPV, 3TC/ddI/EFV; 3TC/d4T/EFV, ZDV/3TC/NFV; 3TC/d4T/EFV (n = 2); ZDV/3TC/EFV, 3TC/d4T/NVP; ZDV/3TC/
EFV, ABC/ddI/NFV; ZDV/3TC/EFV (n = 2); ZDV/3TC, IDV/NVP, 3TC/ABC/d4T, d4T/EFV/IDV/RTV, 3TC/ABC/d4T, 3TC/ABC/d4T/LPV, 3TC/
ABC/AZT/LPV.Journal of the International AIDS Society 2009, 12:25 http://www.jiasociety.org/content/12/1/25
Page 4 of 10
(page number not for citation purposes)
Frequency of HIV-1 subtype C protease mutations Figure 1
Frequency of HIV-1 subtype C protease mutations. A - The frequency of amino acid mutations in HIV-1 subtype C 
(white) or B (black) protease in drug-naïve patients are reported based on the Stanford HIV drug resistance database. B - 
Amino acids in HIV-1 subtype C protease of Batswana treated patients from Group 1 (white) or Group 2 (black) are reported. 
Where more than one amino acid change may have occurred, the most prevalent amino acid is underlined.
Group 1
Group 2
L10 F/I
K20 R/T/I/M
D30N
R41K
K45Q
M46I
I54V
D60E
Q61 E/D
I62V
L63 P/T/V/I
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A71V
I72V
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T74S
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N88S
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were K103N, V106M and I135V/T, while Y181C and
G190A were more frequent among patients who received
NVP. In Group 2 patients, the Y181C and A98S/G muta-
tions were found in association with the L228R/H muta-
tion, [(J = 66.6, p = 0.0001) and (J = 41.7, p = 0.009),
respectively], while L228R/H was associated with G190A
in Group 1 patients (Table 5). We also observed an asso-
ciation between H221Y and Y181C in Group 1 patients
treated with NVP.
Discussion
This study provides data on drug resistance mutational
profiles in HIV-1 subtype C-infected Batswana patients
who experienced treatment failure between 2002 and
2007. Among novel findings, we have shown that resist-
ance to NFV in these patients seems to involve the K45Q
mutation in association with D30N, and occurs with sim-
ilar frequency (J = 50, p = 0.002) as that previously char-
acterized between D30N and N88D (J = 33.3, p = 0.01).
The L89I mutation was also associated with D30N, sug-
gesting that it may occur early in the establishment of
resistance to NFV. Accumulation of large numbers of PI
mutations may reflect the duration of time that patients
may have been left on a failing regimen [18].
We previously demonstrated a greater propensity for
patients infected by HIV-1 subtype C to develop the K65R
mutation after treatment with ddI-based regimens in first-
line therapy [8]. More recently, high rates of K65R were
also observed among patients from West Africa who
received 3TC/d4T/NNRTI as a first-line regimen [19,20].
High rates of virologic failure have also been reported in
patients with the K65R mutation compared to L74V
[21,22]. Both the L74V and K65R mutations may impact
on subsequent TDF responses in patients who had previ-
ously received ddI [22].
Clearly, these two nucleoside cross-resistance mutations
may compromise a wide array of future nucleoside-based
therapeutic options in treatment-experienced patients. In
the present study, the frequency of the K65R mutation was
low (two of 26 patients). One possible explanation may
be the reversion of the K65R mutation after use of subse-
quent ARV regimens, due to considerations of low viral
fitness. This phenomenon emphasizes the need for more
sensitive assays that can be used for surveillance of resist-
ance mutations.
The high frequency of NNRTI mutations is also disturbing
and raises questions about their use in first-line regimens
in developing countries, where financial constraints may
often compel physicians to keep patients on failing regi-
mens for longer than desirable. In this context, it might be
interesting to conduct a study such as ACTG 5142 [23],
which compared the use of EFV to a first-line PI, in set-
tings where subtype C viruses are predominant.
We also observed several associations involving less com-
mon resistance mutations, such as L228R/H and Y181C (J
= 66.6, p = 0.0001) and A98S/G (J = 41.7, p = 0.009) in
Group 2 patients and L228R/H in association with G190A
in Group 1. We further observed a preferential emergence
of the H221Y mutation in Group1 NVP-treated patients,
who first exhibited the Y181C mutation. Moreover, muta-
tions at positions A98, K101, V106, E138, Y181 and G190
were discovered, and it is not yet known whether these
substitutions will affect clinical responsiveness to new
NNRTIs, such as etravirine (ETV), in HIV-1 subtype C
infections [24]. A review article on the subject of HIV drug
resistance mutations and viral subtypes has recently been
published [25].
Switching from ZDV/3TC to d4T/ddI (Group 2) and sub-
sequent maintenance on a suboptimal NVP-containing
regimen may also have resulted in higher rates of associa-
tion between G190A and TAMs or G190A and L74V. Oth-
Table 2: Frequency of mutations within PR
Mutations Frequency (%) *P value
Group 1 Group 2
L10F/I 23 37 0.23
K20R/T/I/M 34.6 60 0.07
D30N 19.2 25.7 0.43
E35D/N 50 60 0.31
K45Q 3.8 17.14 0.12
M46I 7.7 20 0.19
D60E 23 34.28 0.43
Q61E/D 19 42.8 0.06
I62V 0 11.4 0.11
N88D 11.5 8.6 0.48
N88S 7.7 11.4 0.51
L89M 57.7 57.1 0.51
L89I 19.2 14.3 0.39
L90M 15 28 0.34
*P value: probability of significant differences between groupsJournal of the International AIDS Society 2009, 12:25 http://www.jiasociety.org/content/12/1/25
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ers have shown the co-presence of L74V and Y181C in
patients who failed a NVP-containing regimen [26].
Although the Botswana ARV national programme has
tried to optimize ARV therapy and has changed first- and
second-line regimens to TDF/FTC/NNRTI and ZT/3TC/
LPV/r, respectively, our results remain relevant for other
developing country settings that still use ineffective com-
binations in a context of poor adherence. Indeed, it is
important to understand genotypic resistance patterns in
developing countries where treatment options may be
more limited than those that are available wealthier coun-
tries and in which different viral subtypes may predomi-
nate. Associations such as those between the D30N and
K45Q mutations in PR have not previously been reported.
It is likely that the use of suboptimal therapy may facili-
tate the emergence of novel resistance pathways and that
this will become a major concern in resource-limited set-
tings.
Conclusion
HIV subtype C-infected patients in Botswana who began
therapy with either d4T/ddI- or ZDV/3TC-based regimens
and who failed therapy have developed drug resistance-
associated mutations at high frequency. These mutations
are associated with resistance against each of NRTIs,
NNRTIs, and PIs and include several novel substitutions
relative to those typically observed with subtype B viruses.
Hopefully, the current use of improved treatment regi-
mens in Botswana will mitigate both rates of treatment
failure as well as the future development and transmission
of HIV.
Table 3: Significant correlations of pairs of mutations within PR
Mutations Correlated mutations Pearson coeff. Jaccard coeff. P value (freq cell)
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
L10F/I K20R/T/I/M M46I 36.9 36.7 36.4 33.3 0.13 (15.4) 0.07 (13.5)
D30N A71V 42.8 37.1 37.5 28.5 0.06 (11.5) 0.04 (10.8)
Q61E/D 42.8 37.5 0.06 (11.5)
T74S T74S 65.9 44.4 57.1 43.7 0.005 (15.4) 0.02 (0.02)
N88D N88D 65.9 40.36 50 23 0.008 (11.5) 0.04 (8.1)
N88S 52 33 0.05 (7.7)
K20R/T/I/M E35D/N E35D/N 40.4 50.1 46.7 65.4 0.10 (26.9) 0.006 (45.9)
M46I K45Q 39.7 38.4 0 28.5 0.11 (7.7) 0.03 (16.2)
T74S 46.5 0.03 (15.4)
V77I 39.7 0.11 (7.7)
N88S 39.7 0.11 (7.7)
D30N K45Q K45Q 41 60.5 20 50 0.19 (3.85) 0.002 (13.5)
N88D N88D 74 52.4 60 33.3 0.004 (11.5) 0.01 (8.1)
L89I 50.5 42.8 0.03 (11.5)
E35D/N T74S 48.8 38.5 0.04 (19.2)
M46I A71V 41.5 33.3 0.04 (8.1)
V77I 41.5 33.3 0.04 (8.1)
D60E Q61E/D 48.6 50 0.005 (24.32)
Q61E/D N88S 59 40 0.03 (7.7)Journal of the International AIDS Society 2009, 12:25 http://www.jiasociety.org/content/12/1/25
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Frequency of HIV-1 subtype C reverse transcriptase mutations Figure 2
Frequency of HIV-1 subtype C reverse transcriptase mutations. A - The frequency of amino acid mutations in HIV-1 
subtype C (white) or B (black) reverse transcriptase in drug-naïve patients are reported based on the Stanford HIV drug resist-
ance database. B - Amino acids in HIV-1 subtype C reverse transcriptase of Batswana treated patients from Group 1 (white) or 
Group 2 (black) are reported. Where more than one amino acid change may have occurred, the most prevalent amino acid is 
underlined.
M41L
S48 T/E
E53D
D67N
S68G
L74V/I
A98 G/S
K101E/Q/P/R
K102R/Q/N
K103 N/S
V106 M/I
V108I
L109I/V
E138A
T139 A/P/S
I142 V/T
A158S
I178 L/M
V179E/ D
Y181C
M184V
Y188L
G190A
I202V
H208Y
L210W
T215F
T215Y
T215I
K219 Q/E/H
H221Y
L228 R/H
I243S/T
E248 D/T
D250E
S251D
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K275R/Q
R277K
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D324E
I329L/V
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Table 4: Frequency of mutations within RT.
Mutations Frequency (%) *P value
Group 1 Group 2
NNRTI
A98S/G 26.9 18.9 -
K101E/Q/P/R 19.23 21.6 -
K103N 34.6 48.6 -
V106M 30.8 16.21 -
V108I 15.4 18.9 -
E138A 15.4 27 -
V179E/D 15.3 13.5 -
Y181C 23 27 -
Y188L 0 13.5 -
G190A 23 13.5 -
NRTI (non-TAM)
K65R 7.7 0 -
S68G 19.2 8.1 -
L74V/I 7.7 16.2 -
Q151M 3.8 2.7 -
M184V 61 40.5 -
TAM1
41L 26.9 40.5 -
210W 19.2 18.9 -
215Y 26.9 29.7 -
TAM2
67N 46 67.56 0.07
70R 35 37.8 -
215F 26.9 29.7 -
219Q 34.6 37.8 -
Others
E53D 11.5 13.5 -
K102R/Q/N 15.4 0 -
I135V/T 30.8 45.9 -
T139A/P/S 0 16.2 -
I142V/T 15.4 8.1 -
A158S 23 0 -
S162C/A/T 15.4 24.3 -
I178L/M 19 35 -
I202V 34.6 8 0.008
E203A/K/D 3.8 18.9 -
H221Y 11.5 18.9 -
L228R/H 8 27 0.05
D250E 42.3 40.5 -
K275R/Q 23 8 0.09
D324E 27 8 0.04
*P value: probability of significant differences between groups
Table 4: Frequency of mutations within RT. (Continued)Journal of the International AIDS Society 2009, 12:25 http://www.jiasociety.org/content/12/1/25
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